Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and has a heterogeneous clinical course. Some patients experience an indolent disease course, which does not require treatment or affect their overall quality of life. Other patients present with symptomatic advanced disease that rapidly progresses and requires therapy. For these patients, chemotherapy is the mainstay of treatment and has undergone significant evolution in the past few decades. From alkylating agents to purine analogs, response rates have greatly improved with new chemotherapy regimens. The development of chemoimmunotherapy regimens has also transformed the treatment of CLL. This article will review front-line treatment options for CLL and discuss the updated National Comprehensive Cancer Network guidelines. J Oncol Pharm Practice (2011) 17: 91—103.
Chiorazzi N. , Rai K., Ferrarini M.Chronic lymphocytic leukemia. N Engl J Med2005; 352: 804-15.
4.
National Comprehensive CancerNetwork, Inc. Non-hodgkin’s lymphomas NCCN clinical practice guidelines in oncology (version 2.2009), 2009. Available at: http://www.nccn.org (accessed July 15, 2009).
5.
Yee K., O’Brien S.Chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc2006; 81(8): 1105-29.
6.
Inamdar K., Bueso-Ramos C.Pathology of chronic lymphocytic leukemia: an update. Ann Diagn Pathol2007; 11(5): 363-89.
7.
Hallek M., Cheson B., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H.Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood2008; 111(12): 5446-56.
8.
Cheson B., Bennett J., Grever M., Kay N., Keating M., O’Brien S.National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood1996; 87(12): 4990-7.
9.
Tam C., Wierda W., Lerner S., Keating M.Chronic lymphocytic leukemia: how to assess prognosis in 2007. Clin Leuk2007; 1(3): 162-7.
10.
Döhner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L.Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med2000; 343(26): 1910-6.
11.
Damle R., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood1999 ; 94(6): 1840-7.
12.
Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M.ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med2003; 348(18): 1764-75.
13.
Wierda W., O’Brien S.Initial therapy for patients with chronic lymphocytic leukemia. Semin Oncol2006; 33(2): 202-9.
14.
Cheson B., Bennet J., Rai K., Grever M., Kay N., Schiffer C.Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored Working Group. Am J Hematol1988; 29(3): 152-63.
15.
Micromedex Healthcare Series [intranet database], version 5.1. Greenwood Village, CO: Thomson Healthcare.
16.
Gellhorn A., Hyman G., Ultmann J.Chlorambucil in treatment of chronic lymphocytic leukemia and certain lymphomas . J Am Med Assoc1956; 162(3): 178-83.
17.
Zhu Q., Tan D., Samuel M., Chan E., Linn Y.Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis. Leuk Lymphoma2004; 45(11): 2239-45.
18.
Han T., Ezdinli E., Shimaoka K., Desai D.Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer1973; 31(3): 502-8.
19.
Begleiter A. , Mowat M., Israels L., Johnston J.Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Leuk Lymphoma1996; 23(3-4): 187-201.
20.
CLL Trialists’ Collaborative Group.Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst1999; 91(10): 861-8.
21.
Leporrier M. , Chevret S., Cazin B., Boudjerra N., Feujier P., Desablens B. et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood2001; 98(8): 2319-25.
Samonis G., Kontoyiannis D.Infectious complications of purine analog therapy. Curr Opin Infect Dis2001; 14(4): 409-13.
24.
Raphael B., Andersen J., Silber R., Oken M., Moore D., Bennett J. et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol1991; 9(5): 770-6.
25.
Rai K., Peterson B., Appelbaum F., Kolitz J., Elias L., Shepherd L. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med2000; 343(24): 1750-7.
26.
Flinn I., Neuberg D., Grever M., Dewald G., Bennett J., Paietta E. et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol2007 ; 25(7): 793-8.
27.
Eichhorst B. , Busch R., Hopfinger G., Pasold R., Hensel M., Steinbrecher C. et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood2006; 107(3): 885-91.
28.
Catovsky D. , Richards S., Matutes E., Oscier D., Dyer M., Bezares R. et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomized controlled trial. Lancet2007; 370(9583): 230-9.
29.
Robak T., Bloński J., Kasznicki M., Konopka L., Ceglarek B., Dmoszynska A. et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients. Br J Haematol2000; 108(2): 357-68.
30.
Robak T., Bloński J., Kasznicki M., Gora-Tybor J., Dmoszynska A., Wojtaszko M. et al. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). Med Sci Monit2005; 11(10): P171-9.
31.
Robak T., Blonski J., Gora-Tybor J., Jamroziak K., Dwilewicz-Trojaczek J., Tomaszewska A. et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood2006; 108(2): 473-9.
32.
Dillman R., Mick R., McIntyre O.Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. J Clin Oncol1989; 7(4): 433-8.
Knauf W., Lissichkov T., Aldaoud A., Liberati A., Loscertales J., Herbrecht R. et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol2009; 27(26): 4378-84.
35.
Quintás-Cardama A., O’Brien S.Targeted therapy for chronic lymphocytic leukemia . Target Oncol2009; 4(1): 11-21.
36.
Genentech, Inc.Rituxan (rituximab) package insert. San Francisco, CA, 2008 .
Hainsworth J., Litchy S., Barton J., Houston G., Hermann R., Bradof J. et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol2003; 21(9): 1746-51.
39.
Di Gaetano N., Xiao Y., Erba E., Bassan R., Rambaldi A., Golay J. et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol2001; 114(4): 800-9.
40.
Byrd J., Peterson B., Morrison V., Park K., Jacobson R., Hoke E. et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood2003; 101(1): 6-14.
41.
Tam C., Wolf M., Prince H., Januszewicz E., Westerman D., Lin K. et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma . Cancer2006; 106(11): 2412-20.
42.
Keating M., O’Brien S., Albitar M., Lerner S., Plunkett W., Giles F. et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol2005; 23(18): 4079-88.
43.
Tam C., O’Brien S., Wierda W., Kantarjian H., Wen S., Do K. et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood2008; 112(4): 975-80.
44.
Hallek M., Fingerle-Rowson G., Fink A., Busch R., Mayer J., Hensel M. et al. Immunochemotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival of previously untreated patients with advanced chronic lymphocytic leukemia (CLL) [abstract]. In: Proceedings of the 50th Annual Meeting of the American Society of Hematology , 6-9 December, San Francisco, CA. Blood 2008; 112: Abstract 325.
45.
Kay N., Geyer S., Call T., Shanafelt T., Zent C., Jelinek D. et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood2007; 109(2): 405-11.
46.
Shanafelt T. , Lin T., Geyer S., Zent C., Leung N., Kabat B. et al. Pentostatin, cyclophosphamide, and rituximab in older patients with chronic lymphocytic leukemia. Cancer2007; 109(11): 2291-8.
47.
Hillmen P., Skotnicki A., Robak T., Jaksic B., Dmoszynska A., Wu J. et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic Leukemia. J Clin Oncol2007; 25(35): 5616-23.
48.
Lozanski G. , Heerema N., Flinn I., Smith L., Harbison J., Webb J. et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood2004; 103(9): 3278-81.
49.
Wierda W., O’Brien S., Faderl S., Ferrajoli A., Koller C., Estrov Z. et al. CFAR, an active frontline regimen for high-risk patients with CLL, including those with del 17p [abstract]. In: Proceedings of the 50th Annual Meeting of the American Society of Hematology, 6-9 December, San Francisco, CA. Blood 2008; 112: Abstract 2095.
